Biomedical Bonding announces that Evelina Mikaelson has been appointed new CEO effective January 1st, 2023. This strategic appointment follows a comprehensive search process initiated after the founder and CEO Professor Michael Malkochs decision to step down as CEO as the company enters a more expansive commercial phase.
Biomedical Bonding AB is establishing a new paradigm in bone fracture fixation and restoration surgery based on its technological platform Bonevolent™ – bone-like medical adhesives and composite implants. Bonevolent™ products provide surgeons with unprecedented freedom to individualize patient implants during the treatment with emphasis on improved surgical outcome.
The Board is grateful for the time and efforts made by Michael Malkoch as CEO. The appointment of Evelina Mikaelson is an important step in the strategic plan to accelerate BMB’s commercial journey, with Prof Malkoch remaining highly active in the company as Chairman of the Board and Chief Scientific Officer, says Lena Söderström, Board member.
Evelina Mikaelson has an M.Sc. from Uppsala University in business, economics, and law and she has extensive experience in sales management from previous positions as Head of Business for various companies and business units within the Adlibris group. Most recently she holds an executive position within explorative digital development and innovation at The Agency for digital Government.
Ms Mikaelson will commence as CEO on January 1st, 2023, and her top three priorities will be to (i) lead the development and implementation of BMB’s strategic plan; (ii) deepen relationships with key opinion leaders and increase synergies with key stakeholders and (iii) ensure that sales will accelerate in the veterinary market during 2023.